InterMune Company Profile (NASDAQ:ITMN)

About InterMune (NASDAQ:ITMN)

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ITMN
  • CUSIP: 45884X10
  • Web: N/A
Average Prices:
  • 200 Day Moving Avg: $68.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -55.56
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for InterMune (NASDAQ:ITMN)

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Who are some of InterMune's key competitors?

How do I buy InterMune stock?

Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InterMune's stock price today?

One share of InterMune stock can currently be purchased for approximately $73.89.


MarketBeat Community Rating for InterMune (NASDAQ ITMN)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for InterMune (NASDAQ:ITMN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for InterMune (NASDAQ:ITMN)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for InterMune (NASDAQ:ITMN)
Earnings by Quarter for InterMune (NASDAQ:ITMN)
Earnings History by Quarter for InterMune (NASDAQ ITMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details
7/23/2012$0.10$0.01ViewN/AView Earnings Details
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details
2/16/2011$0.64$3.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for InterMune (NASDAQ:ITMN)
Current Year EPS Consensus Estimate: $-2.74 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS

Dividends

Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for InterMune (NASDAQ:ITMN)
Insider Trades by Quarter for InterMune (NASDAQ:ITMN)
Insider Trades by Quarter for InterMune (NASDAQ:ITMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.00View SEC Filing  
5/8/2014Sean NolanVPSell2,644$35.85$94,787.40View SEC Filing  
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.32View SEC Filing  
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View SEC Filing  
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View SEC Filing  
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View SEC Filing  
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View SEC Filing  
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View SEC Filing  
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for InterMune (NASDAQ:ITMN)
Latest Headlines for InterMune (NASDAQ:ITMN)
Source:
DateHeadline
finance.yahoo.com logoTop Analyst Upgrades and Downgrades: Foot Locker, CBOE, InterMune, US Steel and More
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logo[video] Pisani: Ideal conditions for stock owners
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoMarkets Open Higher; Burger King In Talks To Buy Tim Hortons
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logo[video] Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logo[video] Unusual Activity: InterMune
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoETFs for Hedge Funds’ Favorite Pharma Stocks
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoStocks End Higher; S&P 500 Pulls Back From 2,000 Level
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoSummer Rally Contiues on Lower Volume
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoInterMune (ITMN) Worth Watching: Stock Rises 35.4%
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoStock Market News for August 26, 2014
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoRoche Furthers Immunotherapy Program with SP142 Launch
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoCelgene, Gilead Lead Big Biotech Stock Movers
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoMarkets Reverse Early Morning Losses; Still Lower On The Day
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoETF Performance Report: An August to Remember
finance.yahoo.com - April 7 at 10:31 AM
finance.yahoo.com logoWhen does the biotech party end?
finance.yahoo.com - April 7 at 10:31 AM
uk.finance.yahoo.com logoEx-InterMune executive, friend found liable for insider trading
uk.finance.yahoo.com - November 14 at 5:56 PM
finance.yahoo.com logoYour jet-black iPhone 7 might not look new for long
finance.yahoo.com - September 15 at 6:08 PM
nytimes.com logoThe Push and Pull of Gender for Muslims at the Hajj
www.nytimes.com - September 15 at 6:08 PM
nbcnews.com logoNetflix's 'White Helmets' Highlights a Syrian Rescue Group on the Front Line
www.nbcnews.com - September 15 at 6:08 PM
nytimes.com logoIndians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh Festival
www.nytimes.com - September 15 at 6:08 PM
finance.yahoo.com logoInterMune drug may offer big upside to Roche if aimed at liver
finance.yahoo.com - August 27 at 5:58 PM
finance.yahoo.com logoUS STOCKS-Futures point to higher open; S&P 500 near record
finance.yahoo.com - August 25 at 8:51 AM
finance.yahoo.com logoUS STOCKS-Futures rise on hopes for ECB action, merger activity
finance.yahoo.com - August 25 at 7:22 AM
latimes.com logoRoche to buy California biotech firm InterMune for $8.3 billion
www.latimes.com - August 24 at 7:29 PM
finance.yahoo.com logoInterMune taps banks as it braces for buyout bids -sources
finance.yahoo.com - August 13 at 1:13 PM

Social

Chart

InterMune (ITMN) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff